Immunoliposomal fenretinide: A novel antitumoral drug for human neuroblastoma

Cancer Letters

Volumn 197, Issue 1-2, 2003, Pages 151-155

  Raffaghello, L ^a   Pagnan, G ^a   Pastorino, F ^a   Cosimo, E ^a   Brignole, C ^a   Marimpietri, D ^a   Bogenmann, E ^b   Ponzoni, M ^a   Montaldo, P G ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Adjuvant therapy; Anti GD2; Apoptosis; Fenretinide; Immunolipsomes; Liposomes; Metastasis; Neuroblastoma; Retinoid

Indexed keywords

ANTINEOPLASTIC AGENT; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD2; IMMUNOLIPOSOME; RETINOID FENRETINIDE; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER INHIBITION; COMPETITIVE INHIBITION; CONFERENCE PAPER; DRUG BINDING; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; IN VITRO STUDY; MELANOMA CELL; METASTASIS; METASTASIS INHIBITION; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL;

EID: 0037767745     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00097-1     Document Type: Conference Paper

References (12)

1. Seeger R.C., Reynolds C.P. Neoplasms in children, Neuroblastom. Holland J.F., Frei E., Bast R.C., Kufe D.W., Morton D.L., Weichselbaum R.R. Cancer Medicine. 1993;2172-2184 Lea and Febiger, Philadelphia, PA.
2. Marx J. Cell death studies yield cancer clues. Science. 279:1993;760-761.
3. Ponzoni M., Bocca P., Chiesa V., Decensi A., Pistoia V., Raffaghello L., Rozzo C., Montaldo P.G. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res. 55:1995;853-861.
4. Pagnan G., Caridi G., Montaldo P.G., Bado M., Chiesa V., Allen M.T., Ponzoni M. Apoptosis of human neuroblastoma cells induced by liposome-encapsulated Fenretinide. J. Liposome Res. 8:1998;401-423.
5. Formelli F., Clerici M., Campa T., DiMauro M.G., Agni A., Mascotti G., Moglia D., DePalo G., Costa A. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J. Clin. Oncol. 11:1993;2036-2042.
6. Lopes-De-Menezes D.E., Pilarski L.M., Allen T.M. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 8:1998;3320-3330.
7. Mujoo K., Cheresh D.A., Yang H.M., Reisfeld R.A. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolisis and suppression of tumor growth. Cancer Res. 47:1986;1098-1104.
8. Pagnan G., Montaldo P.G., Pastorino F., Raffaghello L., Kirchmeier M., Allen T.M., Ponzoni M. GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped Fenretinide. Int. J. Cancer. 81:1999;268-274.
9. Montaldo P.G., Pagnan G., Pastorino F., Chiesa V., Raffaghello L., Kichmeier M., Allen T.M., Ponzoni M. N-(4-hydroxyphenyl)retinamide is cytotoxic to melanoma cell in vitro through induction of programmed cell death. Int. J. Cancer. 81:1999;262-267.
10. Bogenmann E. A metastatic neuroblastoma model in SCID mice. Int. J. Cancer. 67:1996;381-386.
11. Ozkaynak M.F., Sondel P.M., Krailo M.D., Gan J., Javorsky B., Reisfeld R.A., Matthay K.K., Reaman G.H., Seeger R.C. Phase I study of chimeric human/murine anti-Ganglioside GD2 monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a children's cancer group study. J. Clin. Oncol. 18:2000;4077-4085.
12. Cheung N.-K.V., Yu A.L. Immunotherapy of neuroblastoma. Brodeur G.M., Sawada T., Tsuchida Y., Voute P.A. Neuroblastoma. 2000;541 Elsevier, Amsterdam.